Literature DB >> 15741302

Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.

Kyoung Ju Kim1, Seung Jae Huh, Jung-Hyun Yang, Won Park, Seok Jin Nam, Jeong Han Kim, Jee Hyun Lee, Sung Soo Kang, Jeong Eun Lee, Min Kyu Kang, Young Je Park, Hee Rim Nam.   

Abstract

BACKGROUND: The purpose of this study was to analyze the prognostic factors affecting local control and survival rates for patients with early breast cancer who received breast conserving treatment (BCT) and to find out the optimal treatment according to their risk factors.
METHODS: From October 1994 to December 2001, 605 patients with 611 stage I and II breast cancers received BCT, and the results were analyzed retrospectively. BCT consists of breast conserving surgery and whole breast irradiation. All the patients underwent lumpectomy or quadrantectomy. Axillary lymph node dissection or sentinel lymph node biopsy was performed in 608 cases (99.5%). The radiation dose to the whole breast was 50.4 Gy over 5 weeks with a 1.8 Gy daily fraction and with boost doses of 9-14.4 Gy administered to the tumor bed. Adjuvant chemotherapy was performed in most of the patients with axillary lymph node metastasis or tumors larger than 1 cm. The median follow-up period was 47 months.
RESULTS: Local relapse, regional relapse and distant metastasis occurred in 15 (2.5%), 16 (2.6%) and 43 patients (7.1%), respectively. The 5-year overall survival, local-relapse-free survival, distant-metastasis-free survival and disease-free survival rates were 95.3%, 97.2%, 91.3% and 88.5%, respectively. On multivariate analysis, age (P = 0.02), number of involved axillary lymph nodes (P = 0.01) and nuclear grade (P = 0.01) affected the local-relapse-free survival. The factors associated with disease-free survival were the T stage (P = 0.05), number of involved axillary lymph nodes (P = 0.01) and nuclear grade (P = 0.001). Overall survival was associated with the T stage (P = 0.02), number of involved axillary lymph nodes (P = 0.01) and c-erb B2 overexpression (P = 0.05). Patients with more than two factors among (i) age </=35 years, (ii) positive lymph node metastasis and (iii) high nuclear grade showed a poor 5-year local-relapse-free survival rate compared with others (P = 0.001). Also, patients with more than two factors among (i) tumor size >1 cm, (ii) positive lymph node metastasis and (iii) high nuclear grade showed an inferior 5-year disease-free survival rate compared with others (P = 0.0005).
CONCLUSIONS: The most important prognostic factor affecting local control, disease-free survival and overall survival was axillary lymph node metastasis. The nuclear grade influenced local control and disease relapse. Patients with multiple unfavorable risk factors such as positive axillary lymph nodes, high nuclear grade, young age and large tumor showed poorer local control and disease-free survival than patients without any risk factors, and so more aggressive treatment is required for these patients.

Entities:  

Mesh:

Year:  2005        PMID: 15741302     DOI: 10.1093/jjco/hyi039

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  17 in total

1.  Diagnostic Accuracy and Impact on Management of Ultrasonography-Guided Fine-Needle Aspiration to Detect Axillary Metastasis in Breast Cancer Patients: A Prospective Study.

Authors:  María Jesús Diaz-Ruiz; Anna Arnau; Jesus Montesinos; Ana Miguel; Pere Culell; Lluis Solernou; Lidia Tortajada; Carmen Vergara; Carlos Yanguas; Rafael Salvador-Tarrasón
Journal:  Breast Care (Basel)       Date:  2015-12-07       Impact factor: 2.860

2.  Postoperative periclavicular radiotherapy in breast cancer patients with 1-3 positive axillary lymph nodes. Outcome and morbidity.

Authors:  A Biancosino; M Bremer; J H Karstens; C Biancosino; A Meyer
Journal:  Strahlenther Onkol       Date:  2012-03-14       Impact factor: 3.621

3.  The effect of simulation on recurrence after breast-conserving surgery and radiotherapy: preliminary results.

Authors:  Ji-Yoon Kim; Yeon-Sil Kim; Mi-Ryung Ryu; Sung-Whan Kim; Chul-Seung Kay; Sei-Chul Yoon; Woo-Chan Park; Byung-Joo Song; Se-Jeong Oh; Sang-Seol Jung; Jong-Man Won; Seung-Nam Kim; Su-Mi Chung
Journal:  Cancer Res Treat       Date:  2006-02-28       Impact factor: 4.679

4.  Association between well-known histopathological criteria and overall survival in invasive ductal carcinoma.

Authors:  Aysenur Deger; Filiz Ozyigit; Ozlem Arik; Fatih Ekici; Ahmet Cinkaya; Mahir Tayfur; Hakki Deger
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy.

Authors:  Kyubo Kim; Eui Kyu Chie; Wonshik Han; Dong-Young Noh; In Ae Park; Do-Youn Oh; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang; Sung W Ha
Journal:  J Korean Med Sci       Date:  2010-01-25       Impact factor: 2.153

6.  Factors affecting survival of women diagnosed with breast cancer in El-Minia Governorate, Egypt.

Authors:  Amany Edward Seedhom; Nashwa Nabil Kamal
Journal:  Int J Prev Med       Date:  2011-07

7.  Prevalence of breast cancer in a defined population of iran.

Authors:  A Rezaianzadeh; S T Heydari; H Hosseini; A A Haghdoost; E Barooti; K B Lankarani
Journal:  Iran Red Crescent Med J       Date:  2011-09-15       Impact factor: 0.611

8.  Analysis of prognostic factors and treatment modality changes in breast cancer: a single institution study in Korea.

Authors:  Won-Suk Lee; Jeong Eon Lee; Jung Han Kim; Seok Jin Nam; Jung-Hyun Yang
Journal:  Yonsei Med J       Date:  2007-06-30       Impact factor: 2.759

9.  Psychological and Aesthetic Outcomes in Breast Cancer Patients.

Authors:  Maria V Ermoshchenkova; Aziz D Zikiryahodjaev; Igor V Reshetov; Dmitriy S Svyatoslavov; Mikhail Y Sinelnikov
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-07-13

10.  Population-based study of breast cancer in older women: prognostic factors of relative survival and predictors of treatment.

Authors:  Pegdwende Olivia Dialla; Tienhan Sandrine Dabakuyo; Sophie Marilier; Julie Gentil; Patrick Roignot; Ariane Darut-Jouve; Marie-Laure Poillot; Valérie Quipourt; Patrick Arveux
Journal:  BMC Cancer       Date:  2012-10-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.